Our FANTOM program is dedicated to spreading the fruits of our research far and wide. Early career researchers will engage in diverse outreach activities, including collaborative efforts with the ‘Naked Scientists’ and ‘Open Science,’ providing them with comprehensive training in communication skills. They’ll participate in science festivals, like the Cambridge University Science Festival, where they’ll lead engaging activities to demystify topics such as immune system cancers. Through social media, particularly Twitter, and interactions with the press, they’ll share their findings with both professional and lay audiences. All dissemination efforts will recognize the support received from the European Union’s Horizon 2021 Marie Skłodowska-Curie Doctoral Training Networks.

Will Shepheard – Secondment at Miltenyi Biotec
During the secondment, I used the MACS® Matchmaker to measure antibody responses in plasma samples from patients with ALK-positive anaplastic large cell lymphoma (ALK+ ALCL).

Beyond Research: Marketing and Legal Skills for Doctoral Students
Today, we expect much more from doctoral students than just good research. They must also be skilled in marketing and understand the legal aspects.

Katarina Misura´s secondment at Open Science
After months of generating data in the lab, my secondment at Open Science – Lebenswissenschaften im Dialog in Vienna was a refreshing change of perspective, and a reminder of why science communication matters.

Public Engagement – Nicola Mora
During May I attended two engaging conferences where I had the opportunity to present the latest update of my research on Anaplastic Large Cell Lymphoma.

Rebekka Johanna Sabine Salzmann – Secondment at the Medical University of Vienna (MUW).
During my time in the Merkel lab in Vienna, I investigated lipid metabolism in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

Rebekka Johanna Sabine Salzmann (UNIPD) about her research in podcast series
My research focuses on why patients with the same type of cancer can respond very differently to the same treatment. One key reason appears to be the body’s own defense system
